Abrocitinib 100mg Tablets

Abrocitinib 100mg Tablets represent a modern oral therapeutic option for the management of chronic, inflammatory skin conditions. Pharmacologically, the medication functions as a selective Janus kinase 1 (JAK1) inhibitor.

The JAK-STAT signaling pathway is a primary communication route within immune cells. It transmits signals from cytokine receptors on the cell surface directly to the nucleus to trigger an inflammatory response.

In diseases like atopic dermatitis, specific cytokines such as Interleukin-4 (IL-4), IL-5, IL-13, and IL-31 are overproduced. These cytokines are responsible for the intense itching, redness, and skin barrier breakdown associated with flares.

Abrocitinib 100mg Tablets work by entering the cell and selectively blocking the activity of the JAK1 enzyme. This prevents the phosphorylation of STAT proteins, effectively cutting off the signal that tells the cell to produce more inflammatory mediators.

By prioritizing JAK1 inhibition over other kinases like JAK2 or JAK3, the drug aims to dampen the specific inflammatory cascade driving the eczema while minimizing impacts on other physiological processes, such as the production of blood cells regulated by the JAK2 pathway.

Indications / Uses of Abrocitinib 100mg Tablets

Abrocitinib 100mg Tablets are indicated for the treatment of adults and pediatric patients aged 12 years and older with refractory, moderate-to-severe atopic dermatitis (eczema). Specific clinical applications include:

• Refractory Disease: Indicated for patients whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
• Symptom Control: Prescribed to achieve rapid and significant reduction in skin itch (pruritus) and to improve the extent and severity of skin lesions.
• Adolescent Use: It is specifically approved for adolescents (12+) who require systemic therapy to manage the physical and psychological burden of severe eczema.
• Maintenance Therapy: Used as a long-term maintenance treatment to prevent flares and maintain clear or almost clear skin.

Key Features

• Selective JAK1 Inhibition: By targeting the JAK1 enzyme, it specifically blocks the signaling of the core cytokines involved in the pathophysiology of atopic dermatitis.
• Oral Dosing: Unlike many advanced eczema treatments that require injections, this is a once-daily oral tablet, offering a convenient alternative for patients with needle aversion.
• Rapid Itch Relief: Clinical trials have shown that patients may experience a meaningful reduction in itching within the first few days of starting the medication.
• Dose Flexibility: The 100mg strength allows for precise titration. It is often used as a starting dose for adolescents or as a maintenance dose for adults to balance efficacy and safety.
• Improved Skin Barrier: By reducing chronic inflammation, the medication allows the skin’s natural barrier to heal, reducing the risk of secondary infections.

Storage for Abrocitinib 100mg Tablets

To ensure the stability and safety of Abrocitinib 100mg Tablets, proper storage is required. Store the medication at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F).

Keep the tablets in their original container to protect them from light and moisture. Do not store the medication in humid areas like bathrooms. Ensure the bottle is tightly closed after every use and kept securely out of the reach and sight of children and pets.

Important Note on Abrocitinib 100mg Tablets

Treatment with Abrocitinib 100mg Tablets carries a Boxed Warning. As a JAK inhibitor, it is associated with an increased risk of serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis.

Patients should be screened for tuberculosis (TB) and viral hepatitis before starting treatment. Regular blood monitoring is required to check for thrombocytopenia (low platelet count) and lymphopenia (low white blood cell count).

Treatment should be interrupted if the platelet count or absolute lymphocyte count drops below specific safety thresholds. Liver enzymes and lipid levels (cholesterol) should also be monitored periodically.

Avoid the use of live vaccines during treatment and immediately prior to initiation. The medication is not recommended for use during pregnancy or breastfeeding. Females of reproductive potential should use effective contraception during treatment and for one month after the last dose. Common side effects include nausea, headache, and nasopharyngitis.